IFN beta-1b - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.42 [0.15, 1.17]< 10%2 studies (2/-)95.1 %some concernnot evaluable moderatecrucial-
clinical improvement (time to event analysis only) 2.13 [0.90, 5.00]> 148%2 studies (2/-)95.8 %some concernnot evaluable moderateimportant-
hospital discharge 3.44 [0.64, 18.49]> 10%1 study (1/-)92.4 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.61 [0.18, 1.99]< 123%2 studies (2/-)79.4 %some concernnot evaluable moderateimportant-
ICU admission 0.40 [0.18, 0.90]< 10%2 studies (2/-)98.6 %some concernnot evaluable moderatenon important-

safety endpoints 00

superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.